Navigation Links
Positive CHMP Opinion for JAVLOR(R) in Metastatic Treatment of Bladder Cancer After Failure of a Prior Platinum-Containing Regimen
Date:6/26/2009

CASTRES, France, June 26 /PRNewswire/ -- Laboratoires Pierre Fabre announce today that the Committee for Medicinal Products for Human Use (CHMP), the scientific advisory committee of the European Medicines Agency (EMEA), has issued a positive opinion supporting approval and is recommending to grant marketing authorisation for JAVLOR(R) as monotherapy in metastatic treatment of bladder cancer (advanced or metastatic transitional cell carcinoma of the urothelial tract after failure of a prior platinum-containing regimen).

CHMP has issued a positive opinion based on two phase II study results and on the only phase III randomized study ever conducted in the indication of metastatic treatment of bladder cancer after failure of a prior platinum-containing regimen.

When the EMEA will grant the marketing authorization, JAVLOR(R) will become the first monotherapy approved in Europe for the treatment of adult patients with advanced or metastatic transitional cell carcinoma of the urothelial tract after failure of a prior platinum-containing regimen, where the expectation is important for both oncologists and patients. In Europe the burden of bladder cancer is significative with an estimated 100.000 new cases and 50.000 deaths annually; most of cases are related to the use of tobacco products.

Jean-Pierre Garnier, Chief Executive Officer of Pierre Fabre SA, stated: "The favourable opinion of the CHMP for JAVLOR(R) confirms the therapeutic interest of our anticancer product, strengthened by the clinical data of our file. Again, it rewards the quality of work done by our colleagues dedicated to R&D. JAVLOR(R) will introduce innovative therapy to physicians and patients in an area considered as an unmet medical need".

This approval is a significant milestone for Laboratoires Pierre Fabre as JAVLOR(R) represents one of the leading products of their pipeline and these positive results rew
'/>"/>

SOURCE Pierre Fabre SA
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. AKELA Pharma Inc. announces positive results for the extension part of its Phase IIb Fentanyl TAIFUN(R) trial
2. UCLA/RAND study shows that many children of HIV-positive parents are not in their custody
3. Blue Cross and Blue Shield of Florida Reports Eighteenth Consecutive Year of Positive Performance
4. Nutrition model stresses positive experience of eating
5. Ultrasound plus mammography finds more cancers, but increases false positives
6. Oncolytics Biotech Inc. reports positive interim results of UK phase Ia/Ib trials
7. PEAK Surgical Announces Positive Surgical Incision Wound Healing Results With the PEAK PlasmaBlade(TM)
8. Facet Solutions AFRS(TM) Implant Demonstrates Positive Clinical Results After One Year Follow Up
9. Evotec Reports Positive Top-Line Results in Phase II Study With EVT 201 in Elderly Insomniacs With Daytime Sleepiness
10. A low prevalence of H pylori in HIV-positive patients
11. Drug Company-Funded Asthma Drug Studies More Positive
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2012)... born with cleft lip, cleft palate and other ... , Patients can face serious airway, feeding, speech ... psychological challenges, Laura Swibel Rosenthal, MD, of Loyola ... June 2012 issue of Otolaryngologic Clinics of ... with craniofacial syndromes is complex," Rosenthal and colleagues ...
(Date:5/22/2012)... 17, 2012) The University of Kentucky Markey Cancer ... a deadly blood and bone marrow disease often caused ... from the Edward P. Evans Foundation, along with a ... syndrome (MDS). , The Evans Foundation grant will fund ... at UK, one at Cincinnati Children,s Hospital, and one ...
(Date:5/22/2012)... tasked itself with the daunting challenge of bringing ... "Mobility to a child in a developing country ... societal engagement versus no societal engagement and individual ... of the Mercyhurst University Institute for Public Health, ... traveled to Guanajuato, Mexico, with a team of ...
(Date:5/22/2012)... By Kathleen Doheny HealthDay Reporter , , TUESDAY, ... linked type 2 diabetes with earlier development of precancerous ... start colorectal screenings at a younger age than others. ... with diabetes should get screenings earlier, possibly at age ... Vu, a clinical gastroenterology fellow at Washington University in ...
(Date:5/22/2012)... TUESDAY, May 22 (HealthDay News) -- Two preliminary studies ... the detection and treatment of pancreatic cancer. On ... they have fashioned a vaccine that, in early trials, ... cancer cells. The team -- from Case Western ... Center at University Hospitals Case Medical Center in Cleveland ...
Breaking Medicine News(10 mins):Health News:Cleft lip/palate cause much more than cosmetic problems 2Health News:Markey receives $6.25 million to study deadly blood and bone marrow disease 2Health News:Markey receives $6.25 million to study deadly blood and bone marrow disease 3Health News:New initiative aims to increase mobility for disabled children worldwide 2Health News:Middle-Aged Diabetics May Need Earlier Colon Checks 2Health News:Middle-Aged Diabetics May Need Earlier Colon Checks 3Health News:Studies See Advances in Detecting, Treating Pancreatic Cancer 2Health News:Studies See Advances in Detecting, Treating Pancreatic Cancer 3Health News:Studies See Advances in Detecting, Treating Pancreatic Cancer 4
... people regain strength and normal use of affected hands ... California, Irvine study. ,Stroke patients with ... release objects after therapy sessions using the Hand-Wrist Assisting ... residual weakness and reduced function of the right hand, ...
... signal a higher risk of delivering prematurely are being ... researchers who presented their work in two abstracts at ... San Francisco. ,In both studies, the ... scores) are more likely to have inflammation and infection. ...
... (NSF)— which occurs only in patients with advanced kidney ... MRI scans, reports a study in the March Clinical ... ,An accompanying editorial identifies specific groups of patients in ... more information is available. Meanwhile, another study in the ...
... and the army have taken recourse to yoga to relieve ... insurgency hit areas. ,A select group of ... six-day yoga camp conducted by Swami Ramdev to enable them ... order to hold regular yoga and psychology camps and classes ...
... People with mesothelioma — a form of cancer associated with ... with a combination// of two cancer drugs, a large multicenter ... cancer that occurs in the lining of the lungs, heart ... no known cure. ,In the study, patients receiving ...
... shows that fluctuations in Vitamin D3 levels control the ... to heal. ,Richard L. Gallo, M.D., Ph.D., ... Dermatology and the Dermatology section of the Veterans Affairs ... between fluctuations of the body’s vitamin D3 and infectious ...
Other Medicine News:Health News:Robotic Therapy Helps Restore Hand Use After Stroke 2Health News:Robotic Therapy Helps Restore Hand Use After Stroke 3Health News:Prematurity More Accurately Predicted by Advances in Proteomic Technology 2Health News:MRI Contrast Agent Linked to Complication in Renal Patients 2Health News:Soldiers Readying to Fight Stress With Yoga 2Health News:Chemo Combination Improves Survival in Asbestos-Related Cancer 2Health News:Chemo Combination Improves Survival in Asbestos-Related Cancer 3Health News:Vitamin D3 Protects Skin from Harmful Microbes 2
(Date:5/23/2012)... Aditya Birla Minacs , a global business solutions ... that it has been awarded: 1. Pharmacy Benefit ... Casualty Pharmacy Benefit Management accreditations from URAC, a ... quality standards for the health care industry. ... organizational quality, customer service, communications, disclosure of pricing ...
(Date:5/23/2012)... -- QRxPharma Limited (ASX: QRX and OTCQX: QRXPY) announced ... (USPTO) issued the Company U.S. Patent No. 8,182,837, which ... method of treatment of pain comprising the administration of ... of MoxDuo IR (Immediate Release) for the treatment of ... for the treatment of chronic pain. "This ...
(Date:5/23/2012)... May 23, 2012  Insmed Incorporated (Nasdaq CM: INSM), ... screening patients for its U.S. phase 2 clinical trial, ... R ealize G reater E fficacy ... for inhalation) in patients with non-tuberculous mycobacterial (NTM) lung ... clinical trials to support current NTM treatment recommendations, and ...
Breaking Medicine Technology:Minacs Receives New URAC Pharmacy Benefit Management Accreditations 2Minacs Receives New URAC Pharmacy Benefit Management Accreditations 3QRxPharma Granted Additional US Patent on MoxDuo® 2QRxPharma Granted Additional US Patent on MoxDuo® 3Insmed Incorporated Begins Screening Patients For TARGET-NTM U.S. Clinical Trial Of ARIKACE® In Patients With Non-tuberculous Mycobacterial Lung Disease 2Insmed Incorporated Begins Screening Patients For TARGET-NTM U.S. Clinical Trial Of ARIKACE® In Patients With Non-tuberculous Mycobacterial Lung Disease 3Insmed Incorporated Begins Screening Patients For TARGET-NTM U.S. Clinical Trial Of ARIKACE® In Patients With Non-tuberculous Mycobacterial Lung Disease 4Insmed Incorporated Begins Screening Patients For TARGET-NTM U.S. Clinical Trial Of ARIKACE® In Patients With Non-tuberculous Mycobacterial Lung Disease 5Team24 News Article New EU Directive Offers a Healthy Outlook for Niche Recruitment Companies like Team24 52479 1Team24 News Article New EU Directive Offers a Healthy Outlook for Niche Recruitment Companies like Team24 52479 2Team24 News Article New EU Directive Offers a Healthy Outlook for Niche Recruitment Companies like Team24 52479 3Takeda Provides Update on the Investigational Fixed Dose Combination of alogliptin and ACTOS 28R 29 28pioglitazone HCl 29 4769 1Takeda Provides Update on the Investigational Fixed Dose Combination of alogliptin and ACTOS 28R 29 28pioglitazone HCl 29 4769 2Takeda Provides Update on the Investigational Fixed Dose Combination of alogliptin and ACTOS 28R 29 28pioglitazone HCl 29 4769 3Response Genetics Announces 244 Million Private Placement 13158 1Response Genetics Announces 244 Million Private Placement 13158 2Response Genetics Announces 244 Million Private Placement 13158 3
... III Trial Based on Human Data Demonstrating Bioequivalence of INS-19 ... ... Va., July 10, 2008 Insmed Inc.,(Nasdaq: INSM ), a ... that it has demonstrated the,bioequivalence of INS-19, the company,s recombinant human ...
... TSE Mothers Index: 4565), the biopharmaceutical company, today,announced ... trial for the,emergency contraceptive pill (ECP) SOH-075 (NorLevo(R)). ... in Japan from HRA Pharma., The clinical ... prevented,pregnancy rate of SOH-075 in Japanese adult female ...
Other Medicine Technology:Insmed Announces First Human Bioequivalence Data for a Follow-on Biologic by a U.S. Company 2Insmed Announces First Human Bioequivalence Data for a Follow-on Biologic by a U.S. Company 3Insmed Announces First Human Bioequivalence Data for a Follow-on Biologic by a U.S. Company 4Insmed Announces First Human Bioequivalence Data for a Follow-on Biologic by a U.S. Company 5Sosei Announces Completion of Phase III Trial for NorLevo(R) 2
Rosenbaum card fits in the pocket (3.5 by 6.5") and shows point, Jaeger and distance equivalents from 20/800 to 20/20. Uses numbers, directional Es and XO patterns. For use at 14" (35 mm). Includes f...
... contemporary reading card provides familiar reading ... for trains, flights, football and basketball, ... cards, recipes, want ads, instructions, telephone ... listings. Continuous format reading examples provided ...
Spanish reading test....
Standard reading test. Music Bars and Tables...
Medicine Products: